TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05090865

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Liberalized dietary potassium via fruits and vegetables
Description: On the liberalized dietary potassium intervention, participants will receive groceries delivered to their houses that contain potassium rich fruit and vegetables, that contain more than 250 mg of potassium per typical serving. Participants will be instructed to incorporate the fruit and vegetables into their diet targeting a daily intake of 2000 mg of potassium a day from delivered fruit and vegetables, and a daily dietary potassium intake of 3500 mg.
Study: NCT04956952

Intervention type: DEVICE
Group type: OTHER
Intervention: EECP
Description: 1 hour of treatment with EECP
Study: NCT05090865

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Liberalized dietary potassium via fruits and vegetables
Description: On the liberalized dietary potassium intervention, participants will receive groceries delivered to their houses that contain potassium rich fruit and vegetables, that contain more than 250 mg of potassium per typical serving. Participants will be instructed to incorporate the fruit and vegetables into their diet targeting a daily intake of 2000 mg of potassium a day from delivered fruit and vegetables, and a daily dietary potassium intake of 3500 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Standard dietary potassium restriction
Description: Participants will receive weekly supplementation of lower potassium fruit and vegetables, that deliver less than 200 mg of potassium per typical serving. Participants will be instructed to incorporate the fruit and vegetables into their diet targeting a daily intake of 500 mg of K a day from the box, and a daily dietary K intake \< 2000 mg. Participants will receive counselling from a registered dietician (RD) to reinforce the potassium restriction.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Standard dietary potassium restriction
Description: Participants will receive weekly supplementation of lower potassium fruit and vegetables, that deliver less than 200 mg of potassium per typical serving. Participants will be instructed to incorporate the fruit and vegetables into their diet targeting a daily intake of 500 mg of K a day from the box, and a daily dietary K intake \< 2000 mg. Participants will receive counselling from a registered dietician (RD) to reinforce the potassium restriction.
Study: NCT05846893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SeQuent® Please NEO drug-coated balloon catheter
Description: Treatment of coronary artery disease with SeQuent® Please NEO for de novo lesions in native large coronary arteries

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Current-generation drug-eluting stent
Description: Treatment of coronary artery disease with current-generation drug-eluting stent for de novo lesions in native large coronary arteries
Study: NCT05213234

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Chronotherapy
Description: Chronotherapy is a behavioral intervention that has the intended effect of maximizing therapeutic benefit of a drug by coordinating intake times and biological rhythms.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Chronotherapy
Description: Chronotherapy is a behavioral intervention that has the intended effect of maximizing therapeutic benefit of a drug by coordinating intake times and biological rhythms.
Study: NCT05971173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Juven
Description: Nutritional supplements

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centrum Silver 50+
Description: Over the counter nutritional supplement
Study: NCT05770570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: In-person individual diet and physical activity (PA) counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messages
Description: Thrice-weekly diet/physical activity(PA) text messages

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Phone calls
Description: Weekly telephone support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone calls
Description: Weekly telephone support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring tools
Description: Self-monitoring tools
Study: NCT04683562

Intervention type: OTHER
Group type: OTHER
Intervention: Pregnant women at 28-32 weeks
Description: Pregnant women at gestational age 28-32 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Pregnant women at 28-32 weeks
Description: Pregnant women at gestational age 28-32 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: at delivery
Description: women delivered at term

Intervention type: OTHER
Group type: OTHER
Intervention: at delivery
Description: women delivered at term
Study: NCT04810481

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIS Complete Monitoring System
Description: The BIS™ complete monitoring system is a user-configurable patient monitoring system designed to monitor the hypnotic state of the brain based on the acquisition and processing of EEG signals. The BIS™ complete system processes raw EEG signals to produce a single number, called the BIS™ index, which correlates with the patient's level of hypnosis. A sensor placed on the patient's head transmits EEG signals to the BISx™ unit. The BIS™ unit filters and digitizes the signal, analyzes it for the artifact, and processes it using digital signal processing techniques to derive processed EEG parameters to a single Bispectral Index (BIS™), and finally sends the processed data to the monitor for display. The purpose of processing the EEG waveform data is to extract characteristic features from the complex signal that the BIS™ algorithm can utilize to derive BIS Index.
Study: NCT05770570

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-monitoring tools
Description: Self-monitoring tools
Study: NCT04774445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyCancerGene
Description: Interactive Health Communication Application
Study: NCT05835323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted mini-PCNL
Description: Eligible participants will be enrolled to undergo robotic-assisted PCNL using the MONARCH Platform, Urology for the removal of kidney stones. The MONARCH Platform, Urology is a novel flexible robotic device that enables the clinician to obtain both transurethral and percutaneous access to a participant's kidney under continuous visualization for therapeutic application (for example, stone removal).
Study: NCT04665765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT04327817

Intervention type: DEVICE
Group type: OTHER
Intervention: Multifidus stimulator
Description: Patient eligible for the study and have provided consent will have a baseline PET scan. Multifidus ReActiv8 Stimulator will be inserted using standard treatment for lumbar pain at Barts Health NHS Hospitals.~All patients who receive the Reactiv8 system will continue to receive multifidus stimulation 20Hz for the next 6 months as per standard of care of multifidus stimulation; at the end of this period, the patients will undergo PET scanning and questionnaires. Thereafter, stimulation will continue and 3rd PET scan will be performed at 1year post implant.
Study: NCT04818229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-307
Description: CBP-307 capsules oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matched CBP-307
Description: Placebo-matched CBP-307 capsules oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin (Avelox)
Description: Moxifloxacin tablets oral administration。

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin (Avelox)
Description: Moxifloxacin tablets oral administration。

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-matched Moxifloxacin
Description: Placebo-matched Moxifloxacin tablets oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-matched Moxifloxacin
Description: Placebo-matched Moxifloxacin tablets oral administration.
Study: NCT06641804

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Pessary care, change of pessary
Description: Insertion of a new pessary by gynaecologist if not contraindicated, silicon or polyvinyl chloride pessary of same size, blinded to patient

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pessary care, change of pessary
Description: Insertion of a new pessary by gynaecologist if not contraindicated, silicon or polyvinyl chloride pessary of same size, blinded to patient
Study: NCT06642636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intensive Care Unit-specific Virtual Reality
Description: The Intensive Care specific Virtual Reality (ICU-VR) film is designed so that patients received relevant and truthful information regarding their ICU treatment with the aim to reduce stress and anxiety. The final film lasts approximately 12 minutes. Real ICU nurses and ICU physicians re-enacting a typical day/treatment for a mock patient undergoing ICU treatment. The module will be watched via HMD-VR glasses (PICO G2 VR; Pico Technology, Beijing, China) with the SyncVR Relax \& Distract application (SyncVR, Utrecht, the Netherlands).
Study: NCT06641375

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anti reflux endoscopic theraphy
Description: o the intervention arm, the area of cardia, along greater curvature will be cleaned first followed by demarcation of a 1-1.5 cm area of non-ablation zone with two vertical lines by use of Pulsed APC using the H-APC catheter for marking and to prevent excess ablation . After this, the area of cardia, on either side will be injected in sequence using a combination of methylene blue and normal saline using the H-APC catheter jet system using between Effect 30 and Effect 70 on the ErbeJet 2 to raise the mucosa and create a submucosal cushion . Once adequate submucosal cushion is created, the mucosa starting below the z-line and up to 3 cm below will be treated by Pulsed APC 50W-80W using the H-APC catheter till golden-brown discoloration of the ablated tissue20~The area of cardia below the Z-line will be treated in a 270-320-degree fashion. Once adequate ablation is achieved and no deeper tissue injury or bleeding is ensured, the procedure will be terminated.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Endoscopy
Description: Patients randomized to the control arm, will undergo a sham intervention. This will include performing upper endoscopy with procedural sedation followed by markings of landmarks as described. This will be followed by gastroscope retroflexion in the gastric cardia with at least 15 minute of examination time spent in retroflexion to reciprocate the H-APC intervention. No H-APC or submucosal injection or other intervention will be performed during the upper endoscopy with sham intervention. All Patients will also continue their PPI daily for 4 weeks.
Study: NCT06645093

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Fasting implies 0 kilojoule. Water ad libitum is permitted.
Study: NCT06642909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zuberitamab 600mg
Description: administered twice with a 2-week interval between each dose (i.e. D1, D15). One treatment cycle is 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zuberitamab 1000mg
Description: administered twice with a 2-week interval between each dose (i.e. D1, D15). One treatment cycle is 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: Initial dose of 3.5 mg/kg/d, oral administration, divided into two doses, taken 12 hours apart (Q12h)
Study: NCT06094803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Zentangle Program
Description: Session 1 focuses on Self-awareness and Self-kindness through the Zentangle method. It covers the introduction, basic techniques, and eight steps of Zentangle. Participants practice mindfulness and learn grid and round patterns. Drawing mindfully and interactive sharing are encouraged for engagement and reflection.~Session 2 emphasizes Acceptance and Non-judgmental Attitude. It builds on the previous session, exploring advanced techniques in the Zentangle method. Participants practice mindfulness, learn organic and texturing patterns, create their own artwork, and engage in interactive sharing for reflection.
Study: NCT04968834

Intervention type: GENETIC
Intervention: Genomic profiling
Description: Genomic profiling using CLIA assay
Study: NCT06023264

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: It is a minimally invasive treatment modality. Its effectiveness has been confirmed in numerous studies. It consists of applying an antiseptic in the puncture area and inserting the needle in the required aseptic conditions. During puncture, the patient's physical response is observed at all times, in order to control the local spasmodic responses in each muscle. After applying the technique, we assessed jaw pain, mouth opening, and the appearance of headaches. The adverse effects of the technique are the following: pain after puncture (1.7%), local bleeding at the puncture site (6.1%) and syncopal responses (0.7%).
Study: NCT04938427

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soticlestat placebo-matching mini-tablets or tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat mini-tablets or tablets.
Study: NCT04625660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PQ Bypass System
Description: Intended use from CLN232 Rev A (CLN232 is the DETOUR2 Continued Access Protocol) The PQ Bypass System is intended to improve blood flow in patients with peripheral arterial disease in symptomatic femoropopliteal lesions due to chronic total occlusions ≥ 20 cm that can include de novo, restenotic, or in-stent restenotic lesions; or total lesion lengths ≥24 cm that can include chronic total occlusions or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis.
Study: NCT05299424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM336_group 1
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.04mg of CM336 on the first day of first cycle (C1D1), 0.04mg on C1D8, 0.04mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study: NCT05603104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second-line Antidepressants
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Second-line Antidepressants
Description: See arm description
Study: NCT04678934

Intervention type: PROCEDURE
Intervention: TAVR
Description: Transcatheter aortic valve replacement
Study: NCT05603104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Second-line Antipsychotics
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine hydrochloride
Description: See arm description
Study: NCT05414136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1006
Description: Intravenous fluids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1006
Description: Intravenous fluids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1006
Description: Intravenous fluids
Study: NCT05553119

Intervention type: BEHAVIORAL
Intervention: Home Rehabilitation Monitoring System
Description: Established home-based pulmonary rehab system consists of three commercial devices (Garmin Vívofit™ activity monitor, Nonin 3150 WristOx2® Pulse Oximeter, Android tablet) and two software applications for telemonitored home pulmonary rehabilitation.

Intervention type: BEHAVIORAL
Intervention: Health coaching calls
Description: Coaching calls based on motivational interviewing principles will occur weekly for twelve weeks following a standard protocol, lasting no more than 5-10 minutes.
Study: NCT05414136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1006
Description: Intravenous fluids
Study: NCT05038969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stomopral
Description: 1 capsule contains 40 mg Esomeprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium
Description: 1 capsule contains 40 mg Esomeprazole
Study: NCT05139732

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: In order to investigate the metabolic profile, magnetic resonance spectroscopy (MRS) will be applied. Functional MRI (fMRI) allows to indirectly track cell activation measuring the blood-level dependent signal changes followed spontaneously (in resting state) or evoked by a task. Diffusion weighted imaging (DWI) is based on the differences in motion of the water molecules given by the underlying microarchitecture of the nervous tissue. Diffusion tensor imaging (DTI) allows visualisation of the nerve bundles and alterations thereof. Thus, microstructural alterations can be measured.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: In order to investigate the metabolic profile, magnetic resonance spectroscopy (MRS) will be applied. Functional MRI (fMRI) allows to indirectly track cell activation measuring the blood-level dependent signal changes followed spontaneously (in resting state) or evoked by a task. Diffusion weighted imaging (DWI) is based on the differences in motion of the water molecules given by the underlying microarchitecture of the nervous tissue. Diffusion tensor imaging (DTI) allows visualisation of the nerve bundles and alterations thereof. Thus, microstructural alterations can be measured.
Study: NCT05382286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered intravenously
Study: NCT04719637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRDS-001 Renal Denervation Ultrasound System
Description: Renal Denervation Ultrasound System
Study: NCT06254378

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sinus lifting with allograft
Description: Participants will receive sinus lifting and allograft with immediate implant in premolar-molar area.
Study: NCT06362629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence assistant decision-making system (AIADMS) App
Description: Participants will be assisted to use the Artificial Intelligence assistant decision-making system (AIADMS) app during the process of management of AD, and be followed-up at the scheduled time points including 2 weeks, 4 weeks, 8 weeks, 12 weeks, 6 months and 12 months after treatment, and the evaluation of five treating objectives including PP-NRS, EASI, SCORAD, POEM, and DLQI should be done on the day of follow-up.
Study: NCT05462262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering control
Description: The initial recommended therapy is 10-20mg atorvastatin plus Ezetimibe, and the type and dosage of drugs can be adjusted according to the situation.
Study: NCT06254378

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sinus lifting without graft
Description: Participants will receive sinus lifting with immediate implant in premolar-molar area without graft
Study: NCT05462262

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-intensity lipid-lowering control
Description: The initial recommended therapy is 10-20mg atorvastatin, and the type and dosage of drugs can be adjusted according to the situation.
Study: NCT05607576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uncovered CGM during radiologic procedures
Description: Dexcom G6 CGM will not be covered during radiologic procedures.
Study: NCT05382286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered intravenously
Study: NCT06016244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen saturation threshold
Description: Oxygen saturation threshold on which supplemental oxygen is decided

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen saturation threshold
Description: Oxygen saturation threshold on which supplemental oxygen is decided
Study: NCT04450550

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VeNS device
Description: VeNS treatment

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham VeNS device
Description: Sham treatment of VeNS
Study: NCT06531018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag 25 MG
Description: Eltrombopag 25 mg daily and Prednisolone 1-2mg/kg, selected by block randomization from Day1 to Day 28. Both investigators and patients will be blinded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 1-2 mg/kg and Placebo(same as eltrombopag 25mg Tablet), selected by block randomization from Day1 to Day 28. Both investigators and patients will be blinded.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone 1-2 mg/kg and Placebo(same as eltrombopag 25mg Tablet), selected by block randomization from Day1 to Day 28. Both investigators and patients will be blinded.
Study: NCT05677347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3923868
Description: GSK3923868 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3923868
Description: GSK3923868 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3923868
Description: GSK3923868 will be administered
Study: NCT05382286

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-Paclitaxel
Description: Administered intravenously
Study: NCT05677347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3923868
Description: GSK3923868 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered